Mein Warenkorb

Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Monomer, MALS verified)

User Reviews
Product Number/Spec
Price
Menge
HLH-H82E8-25ug
$125.00
HLH-H82E8-200ug
$700.00
ETA of in-stock products:2 business days
Gesamtanzahl Product Amount$ 0

Product Details

  • Synonyms

    HLA-A*0201 & B2M & HIV Gag (SLYNTVATL)

  • Source

    Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (HLH-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLYNTVATL peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLYNTVATL).

    Predicted N-terminus: Gly 25 & Ser

    Request for sequence
  • Molecular Characterization

    Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein is produced by co-expression of HLA and B2M loaded with HIV Gag peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa and 13.7 kDa. The protein migrates as 40-43 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • SDS-PAGE

    HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) SDS-PAGE

    Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) SEC-MALS

    The purity of Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) is more than 95% and the molecular weight of this protein is around 48-58 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) SPR

    HIV Gag TCR captured on Protein A Chip can bind Biotinylated HumanHLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) with an affinity constant of 0.345 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

    Protocol

User Reviews
Publish Comment

Background Introduction

HIV (human immunodeficiency virus) is a virus that attacks the body’s immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome). It can be transmitted via the exchange of a variety of body fluids from infected people, such as blood, breast milk, semen and vaginal secretions, And from a mother to her child during pregnancy and delivery. This disease can be managed by treatment regimens composed of a combination of antiretroviral (ARV) drugs. The Human HLA-A*0201 HIV (SLYNTVATL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and SLYNTVATL peptide of the HIV.

Frontier Progress

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • Hintergrund
Kontaktieren Sie uns